Trials / Completed
CompletedNCT00189930
An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients
A Single-blind, Randomized, Controlled, Phase II Study to Evaluate Immunogenicity and Safety of Two Doses of the MVA-nef HIV Vaccine in HIV-1 Infected Patients With CD4 > 250/µl
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to compare two doses of MVA-nef vs. MVA-BN to induce Nef-specific cellular immune response in HIV-1 infected patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MVA-nef | 3 imm.: 5E8\_TCID50 MVA-nef, 1E8\_TCID50 MVA-nef in non-dominant upper arm |
| BIOLOGICAL | IMVAMUNE | 3 immunizations: 1E8\_TCID50 IMVAMUNE |
Timeline
- Start date
- 2005-04-01
- Completion
- 2006-12-01
- First posted
- 2005-09-19
- Last updated
- 2012-10-01
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00189930. Inclusion in this directory is not an endorsement.